India, Oct. 13 -- Biomea Fusion Inc. (BMEA) reported Phase 1 results for BMF-650, its investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist being developed for obesity and metabolic disorders.
The study showed weight reduction across multiple dose cohorts over four weeks, with encouraging tolerability findings.
Obesity is a chronic disease characterized by excess body fat and an increased risk of conditions such as type 2 diabetes and cardiovascular disease. GLP-1 receptor agonists act on pathways involved in appetite regulation and glucose metabolism.
BMF-650 is an investigational oral small-molecule GLP-1 receptor agonist designed to support weight reduction while limiting gastrointestinal adverse effects and simplifyin...